Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Mesothelioma, Malignant Clinical Trials

10 recruiting trials for Mesothelioma, Malignant. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
10
Total Trials
10
Recruiting Now
0
Phase 3 Trials
9
Sponsors

Recruiting Trials

RECRUITINGNCT04981119

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect...

Sponsor: A2 Biotherapeutics Inc.Enrolling: 20016 locations
RECRUITINGPhase 1 / Phase 2NCT06051695

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid...

The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC),...

Sponsor: A2 Biotherapeutics Inc.Enrolling: 47412 locations
RECRUITINGNCT06946498

First Local Anaesthesia Thoracoscopy for Pleural Effusion Diagnosis.

Non randomized study with two groups. The study group includes patients with suspected malignant pleural effusion, in whom the investigation of pleural effusion begins directly...

Sponsor: National and Kapodistrian University of AthensEnrolling: 1001 location
RECRUITINGPhase 1 / Phase 2NCT04104776

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in patients...

Sponsor: Novartis PharmaceuticalsEnrolling: 27520 locations
RECRUITINGPhase 1NCT05568680

SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma

This first-in-human (FIH) trial is designed to assess the safety, feasibility, and potential activity of a single intravenous (IV) dose of SynKIR-110 administered to subjects with...

Sponsor: Verismo TherapeuticsEnrolling: 424 locations
RECRUITINGPhase 2NCT05188859

First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma

This study is a single-arm, open-lable, single-center phase II clinical trial for patients with advanced or metastatic pleural mesothelioma. The aim of this study was to observe...

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical SciencesEnrolling: 292 locations
RECRUITINGPhase 1 / Phase 2NCT05944237

HTL0039732 in Participants With Advanced Solid Tumours

The purpose of this trial is to evaluate a new drug, HTL0039732, that will be administered on its own (as a monotherapy) and in combination with atezolizumab or with other...

Sponsor: Cancer Research UKEnrolling: 1505 locations
RECRUITINGPhase 2NCT06057935

A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma

The purpose of this study is to find out whether intraperitoneal or intravenous chemotherapy given after cytoreductive surgery and HIPEC are effective treatments for people with...

Sponsor: Memorial Sloan Kettering Cancer CenterEnrolling: 6413 locations
RECRUITINGPhase 1NCT06251310

SW-682 in Advanced Solid Tumors

This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable...

Sponsor: SpringWorks Therapeutics, Inc.Enrolling: 1868 locations
RECRUITINGNCT07126509

Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma

Purpose of the study: The main purpose of this research study is to see if a surgery procedure (limited partial pleurectomy and decortication) helps symptoms in people who have...

Sponsor: University of ChicagoEnrolling: 301 location